-- RBC Capital週五發布的一份報告指出，Moderna (MRNA) 的研發管線持續取得進展，癌症疫苗和傳染病計畫的進展支撐了其風險回報更加平衡的狀況。 報告稱，Moderna第一季的業績主要得益於強於預期的COVID-19產品線，主要得益於國際收入的確認。同時，管理層重申了全年收入、研發、銷售、管理及行政費用以及資本支出的預期。 RBC強調了Moderna傳染病研發管線的持續增長勢頭，包括即將取得的流感疫苗監管里程碑、流感-COVID聯合疫苗的進展以及諾羅病毒項目的推進，預計將於今年晚些時候根據病例積累情況公佈相關數據。 在腫瘤領域，RBC指出Moderna即將迎來一些利多因素，包括潛在的III期黑色素瘤輔助治療數據、在ASCO會議上更新的II期臨床試驗結果，以及一項利用其癌症疫苗平台開展的早期非小細胞肺癌關鍵性研究。 加拿大皇家銀行維持對該股的「與產業持平」評級，並將目標價從35美元上調至38美元。 Moderna股價週一上漲超過4%。
Price: $47.57, Change: $+2.20, Percent Change: +4.85%
Expand Energy (EXE) is advancing margin-enhancing commercial initiatives and could see increased shareholder returns through stock buybacks, with its shares trading at a "meaningful discount to peers," RBC Capital Markets said in a report emailed Monday.The firm highlighted a new 1.15 million tonnes per annum LNG offtake agreement tied to Delfin FLNG Vessel 1, which pulls forward prior timelines and supports the company's goal of $0.20 per thousand cubic feet equivalent in margin expansion, equivalent to roughly $500 million in free cash flow, according to the report.Expand Energy remains "on track" to meet its 2026 budget of $2.75 billion to $2.95 billion and production guidance of 7.4 billion to 7.6 billion cubic feet equivalent per day, while retaining flexibility to adjust activity levels in response to weak natural gas prices, the report said.The firm cited encouraging early results from Western Haynesville wells and ongoing leadership transition progress, with a CEO expected in H2 of 2026, and said that after about $1.3 billion in Q2 debt repayment, capital returns are likely to increasingly favor buybacks over "variable dividends," according to the report.RBC has an outperform rating on Expand Energy, with a price target of $145.Price: $99.78, Change: $-0.34, Percent Change: -0.34%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $109 from $132, 12.5x our 2026 EPS estimate of $8.71. We believe this premium multiple is justified by the long-term pent-up demand opportunity and the company's financial flexibility to navigate near-term energy cost pressures. We model a 30-bp operating margin decline in 2026 due to energy costs, which we expect will negate leverage benefits despite modest revenue growth. Our assumptions yield 2026 EPS of $8.71 (revised from $9.54) and 2027 EPS of $9.85 (revised from $10.89). The primary risk to our thesis is the potential for the current energy shock to extend into 2027, which would further weaken consumer demand and likely require downward revisions to future earnings. For now, we expect continued spending from wealthier consumers and a seesawing but present commercial demand to provide a floor for the business. This balance of near-term risk against long-term recovery potential keeps us on the sidelines, awaiting greater clarity on the macroeconomic environment.
Tyson Foods (TSN) has an average rating of hold and mean price target of $68.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $66.19, Change: $+2.51, Percent Change: +3.93%